NIGHTHAWK BIOSCIENCES INC (NHWK) Fundamental Analysis & Valuation
NYSEARCA:NHWK • US42237K4094
Current stock price
0.4135 USD
+0.03 (+8.96%)
At close:
0.4299 USD
+0.02 (+3.97%)
After Hours:
This NHWK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NHWK Profitability Analysis
1.1 Basic Checks
- NHWK had negative earnings in the past year.
- In the past year NHWK has reported a negative cash flow from operations.
1.2 Ratios
- NHWK has a Return On Assets of -74.32%. This is in the lower half of the industry: NHWK underperforms 71.89% of its industry peers.
- With a Return On Equity value of -143.11%, NHWK is not doing good in the industry: 65.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.32% | ||
| ROE | -143.11% | ||
| ROIC | N/A |
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NHWK has a better Gross Margin (28.70%) than 76.43% of its industry peers.
- The Profit Margin and Operating Margin are not available for NHWK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. NHWK Health Analysis
2.1 Basic Checks
- NHWK does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, NHWK has more shares outstanding
- The debt/assets ratio for NHWK is higher compared to a year ago.
2.2 Solvency
- NHWK has an Altman-Z score of -6.72. This is a bad value and indicates that NHWK is not financially healthy and even has some risk of bankruptcy.
- NHWK has a Altman-Z score of -6.72. This is in the lower half of the industry: NHWK underperforms 72.22% of its industry peers.
- NHWK has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
- NHWK has a Debt to Equity ratio of 0.25. This is in the lower half of the industry: NHWK underperforms 71.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.72 |
ROIC/WACCN/A
WACC10.89%
2.3 Liquidity
- A Current Ratio of 0.99 indicates that NHWK may have some problems paying its short term obligations.
- NHWK's Current ratio of 0.99 is on the low side compared to the rest of the industry. NHWK is outperformed by 90.40% of its industry peers.
- A Quick Ratio of 0.99 indicates that NHWK may have some problems paying its short term obligations.
- NHWK has a Quick ratio of 0.99. This is amonst the worse of the industry: NHWK underperforms 89.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 |
3. NHWK Growth Analysis
3.1 Past
- NHWK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.47%.
- The Revenue has grown by 147.78% in the past year. This is a very strong growth!
- Measured over the past years, NHWK shows a very strong growth in Revenue. The Revenue has been growing by 33.23% on average per year.
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%
3.2 Future
- The Earnings Per Share is expected to grow by 18.45% on average over the next years. This is quite good.
- The Revenue is expected to grow by 71.98% on average over the next years. This is a very strong growth
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. NHWK Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for NHWK. In the last year negative earnings were reported.
- Also next year NHWK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- NHWK's earnings are expected to grow with 18.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.97%
EPS Next 3Y18.45%
5. NHWK Dividend Analysis
5.1 Amount
- NHWK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NHWK Fundamentals: All Metrics, Ratios and Statistics
0.4135
+0.03 (+8.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20 2023-11-20/amc
Earnings (Next)03-29 2024-03-29/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap36.34M
Revenue(TTM)2.23M
Net Income(TTM)-51.95M
Analysts43.33
Price Target10.2 (2366.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.76%
Min EPS beat(2)-40.06%
Max EPS beat(2)-15.47%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-14.5%
Min Revenue beat(2)-55.88%
Max Revenue beat(2)26.87%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 16.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1 | ||
| P/tB | 1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.98
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.03
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.32% | ||
| ROE | -143.11% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.7% | ||
| FCFM | N/A |
ROA(3y)-30.52%
ROA(5y)-42.03%
ROE(3y)-37.4%
ROE(5y)-62.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 43.83% | ||
| Cap/Sales | 121.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | -6.72 |
F-Score3
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)351.08%
Cap/Depr(5y)283.29%
Cap/Sales(3y)138.98%
Cap/Sales(5y)87.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
EPS Next Y-16.18%
EPS Next 2Y23.97%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue 1Y (TTM)147.78%
Revenue growth 3Y27.89%
Revenue growth 5Y33.23%
Sales Q2Q%1100%
Revenue Next Year-28.99%
Revenue Next 2Y72.79%
Revenue Next 3Y71.98%
Revenue Next 5YN/A
EBIT growth 1Y-45.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.4%
OCF growth 3YN/A
OCF growth 5YN/A
NIGHTHAWK BIOSCIENCES INC / NHWK Fundamental Analysis FAQ
What is the ChartMill fundamental rating of NIGHTHAWK BIOSCIENCES INC (NHWK) stock?
ChartMill assigns a fundamental rating of 2 / 10 to NHWK.
What is the valuation status for NHWK stock?
ChartMill assigns a valuation rating of 0 / 10 to NIGHTHAWK BIOSCIENCES INC (NHWK). This can be considered as Overvalued.
Can you provide the profitability details for NIGHTHAWK BIOSCIENCES INC?
NIGHTHAWK BIOSCIENCES INC (NHWK) has a profitability rating of 1 / 10.
How financially healthy is NIGHTHAWK BIOSCIENCES INC?
The financial health rating of NIGHTHAWK BIOSCIENCES INC (NHWK) is 0 / 10.
What is the expected EPS growth for NIGHTHAWK BIOSCIENCES INC (NHWK) stock?
The Earnings per Share (EPS) of NIGHTHAWK BIOSCIENCES INC (NHWK) is expected to decline by -16.18% in the next year.